127 related articles for article (PubMed ID: 28881732)
1. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target.
Zheng W; Yao M; Qian Q; Sai W; Qiu L; Yang J; Wu W; Dong Z; Yao D
Oncotarget; 2017 Aug; 8(32):52321-52332. PubMed ID: 28881732
[TBL] [Abstract][Full Text] [Related]
2. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract][Full Text] [Related]
3. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma.
Zheng W; Yao M; Sai W; Qian Q; Pan L; Qiu L; Huang J; Wu W; Yao D
Tumour Biol; 2016 Jan; 37(1):999-1008. PubMed ID: 26264614
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
[TBL] [Abstract][Full Text] [Related]
6. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
7. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Oncol Lett; 2018 May; 15(5):7191-7199. PubMed ID: 29731881
[TBL] [Abstract][Full Text] [Related]
9. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
[No Abstract] [Full Text] [Related]
10. Role of secretory clusterin in hepatocarcinogenesis.
Yao M; Fang M; Zheng W; Dong Z; Yao D
Transl Gastroenterol Hepatol; 2018; 3():48. PubMed ID: 30221206
[TBL] [Abstract][Full Text] [Related]
11. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays.
Bi J; Guo AL; Lai YR; Li B; Zhong JM; Wu HQ; Xie Z; He YL; Lv ZL; Lau SH; Wang Q; Huang XH; Zhang LJ; Wen JM; Guan XY
Neoplasma; 2010; 57(3):191-7. PubMed ID: 20353268
[TBL] [Abstract][Full Text] [Related]
13. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S; Watanabe T; Nagaoka K; Fujimoto N; Furuta Y; Tanaka K; Tokunaga T; Kawasaki T; Yoshimaru Y; Setoyama H; Oniki K; Saruwatari J; Tateyama M; Naoe H; Tanaka M; Tanaka Y; Sasaki Y
Hepatol Commun; 2022 May; 6(5):1198-1212. PubMed ID: 34837478
[TBL] [Abstract][Full Text] [Related]
14. Far-infrared radiation inhibits proliferation, migration, and angiogenesis of human umbilical vein endothelial cells by suppressing secretory clusterin levels.
Hwang S; Lee DH; Lee IK; Park YM; Jo I
Cancer Lett; 2014 Apr; 346(1):74-83. PubMed ID: 24334140
[TBL] [Abstract][Full Text] [Related]
15. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
[TBL] [Abstract][Full Text] [Related]
16. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.
Hu T; Guo H; Wang W; Yu S; Han L; Jiang L; Ma J; Yang C; Guo Q; Nan K
Oncol Rep; 2013 Oct; 30(4):1707-14. PubMed ID: 23842948
[TBL] [Abstract][Full Text] [Related]
17. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
18. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
[TBL] [Abstract][Full Text] [Related]
19. Secretory clusterin is upregulated in rats with pulmonary arterial hypertension induced by systemic-to-pulmonary shunts and exerts important roles in pulmonary artery smooth muscle cells.
Liu X; Meng L; Li J; Meng J; Teng X; Gu H; Hu S; Wei Y
Acta Physiol (Oxf); 2015 Feb; 213(2):505-18. PubMed ID: 25069740
[TBL] [Abstract][Full Text] [Related]
20. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
Luo G; Chao YL; Tang B; Li BS; Xiao YF; Xie R; Wang SM; Wu YY; Dong H; Liu XD; Yang SM
Oncotarget; 2015 Nov; 6(35):37808-23. PubMed ID: 26498692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
